Home » Stocks » CBAY

CymaBay Therapeutics Inc. (CBAY)

Stock Price: $7.46 USD 0.00 (0.00%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $7.50 +0.04 (0.54%) Nov 27, 4:04 PM

Stock Price Chart

Key Info

Market Cap 513.90M
Revenue (ttm) n/a
Net Income (ttm) -64.65M
Shares Out 68.89M
EPS (ttm) -0.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $7.46
Previous Close $7.46
Change ($) 0.00
Change (%) 0.00%
Day's Open 7.21
Day's Range 7.17 - 7.50
Day's Volume 523,412
52-Week Range 1.25 - 9.03

More Stats

Market Cap 513.90M
Enterprise Value 354.02M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 68.89M
Float n/a
EPS (basic) -0.95
EPS (diluted) -0.94
FCF / Share -0.84
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.27M
Short Ratio 4.77
Short % of Float n/a
Beta 1.75
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.28
Revenue n/a
Operating Income -67.27M
Net Income -64.65M
Free Cash Flow -58.09M
Net Cash 159.88M
Net Cash / Share 2.32
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -19.64%
ROE -35.02%
ROIC -54.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (11)

Buy 11
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$13.00*
(74.26% upside)
Low
9.00
Current: $7.46
High
20.00
Target: 13.00
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue--10.00----3.0515.15
Revenue Growth--------79.86%-
Gross Profit--10.00----3.0515.15
Operating Income-108-72.51-21.33-25.59-25.90-24.01-9.40-10.44-3.90
Net Income-103-72.55-27.56-26.67-15.53-31.92244-23.90-4.50
Shares Outstanding67.0357.8134.9023.4518.9012.052.360.010.01
Earnings Per Share-1.53-1.26-0.79-1.14-0.83-2.65-3.54-4,128.71-2,963.11
Operating Cash Flow-97.91-54.94-19.63-23.35-23.32-21.11-8.46-11.29-17.93
Capital Expenditures-0.32-0.53-0.03-0.04--0.100.66--0.04
Free Cash Flow-98.23-55.47-19.66-23.40-23.32-21.22-7.80-11.29-17.96
Cash & Equivalents19117997.2116.9941.4834.8031.247.7319.03
Total Debt1.74-6.108.809.314.514.4513.7413.76
Net Cash / Debt18917991.118.2032.1730.2926.80-6.015.27
Assets20618710419.3643.0837.4732.508.1219.79
Liabilities19.3816.3319.3015.4214.9623.6213.9017.9918.55
Book Value18617084.953.9428.1213.8518.60-329-305
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CymaBay Therapeutics Inc.
Country United States
Employees 36
CEO Sujal Shah

Stock Information

Ticker Symbol CBAY
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CBAY

Description

CymaBay Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.